10x Genomics, Inc.

Listed Company

TXGCIK 0001770787NasdaqLarge AcceleratedLaboratory Analytical InstrumentsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$642.82M

Net Income

$-43.54M

Total Assets

$1.04B

Equity

$796.33M

Shares Out

127.69M

Op. Cash Flow

$136.05M

TXG$43.74+251.33% · past yearDBEQ Basic

Daily closing prices

Business

10x Genomics is a life sciences technology company that develops and sells integrated research solutions comprising instruments, consumables, and software for analyzing biological systems at single-cell and spatial resolution. The company offers three primary product portfolios: Chromium for single-cell analysis, Visium and Xenium for spatial analysis, and accompanying software tools. 10x Genomics sells directly through its sales force in North America and parts of Europe and through third-party distributors globally, serving academic institutions, government agencies, biopharmaceutical companies, and biotechnology firms conducting life sciences research.

Summary from 10-K filed 2026-02-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	643	611	619	516	490
Cost of products and services revenue	199	196	209	120	74
Gross profit	444	414	409	396	416
Research and development	239	265	270	266	212
Selling, general and administrative	316	344	343	298	258
Gain on settlement	−50	0	0	—	—
In-process research and development	0	0	61	0	0
Total operating expenses	505	609	675	564	469
Loss from operations	−61	−195	−265	−168	−52
Interest income	20	19	17	7	206,000
Interest expense	0	−4,000	−33,000	−476,000	—
Other income (expense), net	1	−2	−286,000	−198,000	−802,000
Total other income	21	17	17	6	−1
Loss before provision for income taxes	−40	−178	−249	−162	−54
Provision for income taxes	4	5	6	4	5
Net loss	−44	−183	−255	−166	−58
Net loss per share, basic (in dollars per share)	−0.35	−1.52	−2.18	−1.46	−0.53
Net loss per share, diluted (in dollars per share)	−0.35	−1.52	−2.18	−1.46	−0.53
Weighted-average shares used to compute net loss per share, basic (in shares)	125	120	117	114	110
Weighted-average shares used to compute net loss per share, diluted (in shares)	125	120	117	114	110

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	474	344	359	220	587
Marketable securities	49	49	29	210	0
Accounts receivable, net	47	88	115	104	85
Inventory	56	83	74	82	60
Other receivables	35	606,000	—	—	—
Prepaid expenses and other current assets	22	19	19	17	14
Total current assets	684	584	596	635	748
Property and equipment, net	227	253	280	289	169
Operating lease right-of-use assets	60	57	65	70	61
Goodwill	5	5	5	5	5
Intangible assets, net	62	16	17	23	25
Other noncurrent assets	3	4	3	2	3
Total assets	1,041	919	965	1,029	1,019
Accounts payable	13	13	16	22	17
Accrued compensation and related benefits	43	34	30	33	32
Accrued expenses and other current liabilities	40	41	57	60	—
Deferred revenue	24	21	13	8	5
Operating lease liabilities	11	9	12	9	5
Contingent consideration, current	23	0	—	—	0
Total current liabilities	153	118	127	131	110
Contingent consideration, noncurrent	1	0	—	—	—
Operating lease liabilities, noncurrent	73	73	84	86	77
Deferred revenue, noncurrent	11	13	9	3	—
Other noncurrent liabilities	6	5	4	3	8
Total liabilities	245	209	224	223	201
Commitments and contingencies (Note 7)	—	—	—	—	—
Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or outstanding as of December 31, 2025 and 2024	0	0	0	0	0
Common stock, $0.00001 par value; 1,100,000,000 shares authorized (Class A 1,000,000,000, Class B 100,000,000); 127,691,329 (Class A 117,612,457, Class B 10,078,872) and 122,291,837 (Class A 108,235,004, Class B 14,056,833) shares issued and outstanding as of December 31, 2025 and 2024, respectively	2,000	2,000	2,000	2,000	2,000
Additional paid-in capital	2,307	2,178	2,026	1,839	1,681
Accumulated deficit	−1,511	−1,467	−1,284	−1,029	−863
Accumulated other comprehensive income (loss)	225,000	−493,000	−429,000	−4	22,000
Total stockholders equity	796	710	741	806	818
Total liabilities and stockholders equity	1,041	919	965	1,029	1,019

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Stock-based compensation expense	109	141	167	137	96
Depreciation and amortization	36	36	36	25	21
Asset and lease impairment charges	814,000	3	10	—	—
ROU assets impairment due to restructuring	1	0	0	—	—
Amortization of right-of-use assets	8	8	8	8	7
Fair value adjustments on contingent consideration	1	0	0	—	—
Realized loss on marketable securities	0	3,000	2	0	0
Other	−2	523,000	427,000	2	79,000
Accounts receivable	41	27	−11	−19	−34
Other receivables	−35	0	0	—	—
Inventory	28	−10	8	−21	−30
Prepaid expenses and other current assets	−2	−2	−2	−4	−1
Other noncurrent assets	689,000	−1	−678,000	925,000	1
Accounts payable	−2	−3	−6	6	11
Accrued compensation and other related benefits	8	4	−3	1	16
Deferred revenue	746,000	11	11	3	2
Accrued expenses and other current liabilities	−5	−13	28	3	−873,000
Operating lease liability	−10	−12	−9	−6	−2
Other noncurrent liabilities	1	776,000	1	−3	−5
Net cash provided by (used in) operating activities	136	7	−15	−34	−21
Proceeds from maturities of marketable securities	125	26	83	19	0
Proceeds from sales of marketable securities	0	4	100	49	0
Purchase of marketable securities	−123	−49	0	−283	0
Asset acquisition, net	−9	0	0	—	—
Purchases of property and equipment	−6	−12	−49	−132	−101
Purchase of intangible assets	0	−1	−923,000	0	0
Net cash (used in) provided by investing activities	−13	−33	133	−351	−107
Issuance of common stock from exercise of stock options and employee stock purchase plan purchases	7	11	19	21	40
Payments on technology license financing arrangement	0	0	−6	−5	−5
Net cash provided by financing activities	7	11	14	16	35
Effect of exchange rate changes on cash and cash equivalents	484,000	−164,000	−33,000	−44,000	234,000
Net increase (decrease) in cash and cash equivalents	130	−15	132	−369	−93
Cash paid for interest	0	0	436,000	841,000	1
Cash paid for taxes	2	6	5	4	9
Purchases of property and equipment included in accounts payable, accrued expenses and other current liabilities	215,000	1	3	27	17
Right-of-use assets obtained in exchange for new operating lease liabilities	11	0	7	17	21
Common stock issued for acquisition of assets	14	0	0	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is 10x Genomics, Inc.'s CIK number?

10x Genomics, Inc.'s SEC CIK number is 0001770787 (1770787). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find 10x Genomics, Inc.'s SEC filings?

All of 10x Genomics, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did 10x Genomics, Inc. last report earnings?

10x Genomics, Inc. (TXG) most recently filed an earnings 8-K with the SEC on May 7, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001628280-26-032073). This is 10x Genomics, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is 10x Genomics, Inc.'s most recent earnings 8-K?

10x Genomics, Inc.'s latest earnings 8-K (Item 2.02) was filed May 7, 2026 under accession 0001628280-26-032073. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View 10x Genomics, Inc.'s latest earnings 8-K →
Look up any company's CIK number →